Incyte was granted a patent for A2A and A2B receptor inhibitors.

{
  "signal_id": "762eb116-3817-5b2f-9a4a-a4d52338c0bb",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-09-20T17:42:02+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07D 487/04"
      },
      {
        "code": "C07D 519/00"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In September 2026 Incyte patented drug compounds designed to treat cancer and inflammatory, cardiovascular, and neurodegenerative diseases.",
    "summary": "Incyte was granted a patent for A2A and A2B receptor inhibitors.",
    "event_at": "2026-09-15",
    "inventors": [
      {
        "name": "Xiaozhao Wang",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/xiaozhao-wang-a747155a"
      },
      {
        "name": "Peter Niels Carlsen",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/peter-carlsen-7826aab7"
      },
      {
        "name": "Pei Gan",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/pei-gan-40a8bb10a"
      },
      {
        "name": "Gia Hoang",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/giahoang"
      },
      {
        "name": "Yong Li",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/yong-li-3b8b5413b"
      },
      {
        "name": "Chao Qi",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Liangxing Wu",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/liangxing"
      },
      {
        "name": "Wenqing Yao",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-09-15",
    "source_url": "https://patents.google.com/patent/US12735424",
    "cpc_primary": {
      "code": "C07D 487/04"
    },
    "patent_title": "Fused pyrazine derivatives as A2A / A2B inhibitors",
    "patent_number": "US12735424",
    "uspto_assignee": "Incyte Corporation",
    "patent_abstract": "This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.",
    "precision_class": "structural",
    "invention_explanation": "A family of fused pyrazine-based compounds that blocks selected adenosine receptors, which can help alter disease-related immune and cellular activity.",
    "technologies_mentioned": [
      "medicinal chemistry",
      "adenosine receptor inhibitors",
      "small-molecule therapeutics"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/762eb116-3817-5b2f-9a4a-a4d52338c0bb \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'